Author:
Liang Jin-ping,Mi Rui-hua,Chen Lin,Wei Xu-dong
Reference5 articles.
1. Chronic myeloid leukemia, version 2.2021, NCCN clinical practice guidelines in oncology;Deininger;J Natl Compr Cancer Netw,2020
2. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia;Moslehi;J Clin Oncol,2015
3. Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies;Wang;Expet Rev Clin Pharmacol,2021
4. Discovery of cerebrovascular moyamoya disease: research during the late 1950s and early 1960s;Oshima;Childs Nerv Syst,2012
5. Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells;Gover-Proaktor;Leuk Lymphoma,2019
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献